Table 2.
List of SNPs along with their endpoint conclusion discussed in table with the appropriate references
| High risk SNPs involved in prostate cancer | Investigated gene(s)/loci | Number of cases in the study | Endpoint Conclusion | References |
|---|---|---|---|---|
| rs17021918, rs7679673, rs1447295, rs721048, rs9364554, rs16901979, rs2928679, rs4430796, rs1512268, rs6983267, rs16902094, rs12621278, rs920861, rs1855962, rs4962416, rs2660753, rs10934853, rs7127900, rs10486567, rs12418451, rs10993994, rs8102476, rs10896449, rs2735839, rs5945619, rs5759167, rs1465618 | - | 4621 | Risk prediction models at genetic level lead the identification of a subset of high-risk suspected prostate cancer patients at early curable stage | Sun et al. 2011 [74] |
| rs7841060, rs620861, rs6983267, rs1447295, rs721048, rs4242382, rs12621278, rs7837688, rs4857841, rs16902094, rs12500426, rs1571801, rs9364554, rs10993994, rs6465657, rs4962416, rs1512268, rs7127900, rs1016343, rs12418451, rs16901979, rs7931342, rs1465618, rs10896449, rs2660753, rs11649743, rs4430796, rs7501939, rs1859962, rs17021918, rs266849, rs7679673, rs2735839, rs10486567, rs5759167, rs6465657, rs5945572, rs2928679, rs5945619, rs4961199 | SLC25A37, CPNE3, EHBP1, MSMB, BIK, SLC22A3, ITGA6, TCF2, PDLIM5, EEFSEC, CTBP2, KLK3, TET2, THADA, CNGB3, JAZF1, LMTK2, NUDT11, NKX3-1 | 15161 | Addition of familial history and genetic information apart from PSA screening in predictive risk models of prostate cancer could be beneficial for young suspected prostate cancer patients | Lindstrom et al. 2012 [75] |
| rs721048, rs1465618, rs12621278, rs2660753, rs17021918, rs12500426, rs7679673, rs9364554, rs10486567, rs6465657, rs10505483, rs6983267, rs1447295, rs2928679, rs1512268, rs10086908, rs620861, rs10993994, rs4962416, rs7931342, rs7127900, rs4430796, rs1859962, rs2735839, rs5759167, rs5945619 | - | 2885 | Development of algorithm to predict prostate cancer using familial history and genotypes of more than 25 SNPs. This can be used to assess the pedigrees of an arbitrary population size or structure. | Macinnis et al. 2011 [76] |
| rs2736098, rs11067228, rs10788160, rs17632542 | - | 964 | Combination of genotyping and PSA detection more specifically detect suspected prostate cancer and delay or prevent needless prostate biopsies | Helfand et al. 2013 [88] |
| rs10486567, rs17632542, rs11228565, rs5759167 | JAZF1, IGF2, TPCN2, HNF1B, DPF1, MYC, PPP1R14A, NCOA4, SPINT2, TH, KLK3, INS, TTLL1, MYEOV, BIK, MSMB, NUDT11 | 3772 | Using SNPs for assessing prostate cancer risk is less accurate than PSA detection and there is no advancement in prostate cancer diagnostics using both SNPs and PSA. | Klein et al. 2012 [80] |
| rs721048, rs10993994, rs12621278, rs7127900, rs10086908, rs10896449, rs13252298, rs11649743, rs16901979, rs4430796, rs6983267, rs1859962, rs1016343, rs8102476, rs6983561, rs2735839, rs7679673, rs5759167, rs16902094, rs5945619, rs1447295 | EEFSEC, CTBP2, THADA, HNF1B, ITGA6, PPP1R14A, PDLIM5, KLK3, FLJ20032, TNRC6B, JAZF1, BIK, LMTK2, NUDT11, MSMB, 8q24.21, EHBP1, 11q15.5, SLC22A3, 11q13.2, NKX3-1, 17q24.3 | 5241 | Implementation of risk-prediction and genetic risk score decreases biopsies by 22.7% and missing diagnosis cost of prostate cancer by 3% | Aly et al. 2011 [131] |
| rs8844019 | EGFR | 212 | After radical prostatectomy, the authors observed a strong association between prostate biochemical recurrence and the SNPs | Perez et al. 2010 [132] |
| rs9282861, rs198977, rs11536889 | SULT1A1, KLK2, TLR4 | 703 | After radical prostatectomy predicting biochemical recurrence in prostate cancer were significantly improved by the inclusion of patient genetic information and clinicopathological data interpretation. | Morote et al. 2010 [133] |
| rs2208532, rs4952197, rs12470143, rs518673, rs523349, rs12470143 | SRD5A2, SRD5A1 | 846 | Multiple variations in SRD5A2 and SRD5A1 are associated with either decreased or increased rates of BCR after radical prostatectomy. | Audet-Walsh et al. 2011 [134] |
| rs10895304 | MMP7 | 212 | Predictive analysis of A/G genotype in clinically localized prostate cancer patients reduces recurrence | Jaboin et al. 2011 [135] |
| rs2279115 | bcl2 | 290 | Biochemical recurrence frequency was more observed in -938 A/A genotype carriers than -938 CC + C/A carriers | Bachmann et al. 2011 [136] |
| rs3846716 | APC, CTNNB1 | 307 | After radical prostatectomy, the SNP genotype of AA/GA has promising prognostic role | Huang et al. 2010 [137] |
| rs2016347, rs2946834 | IGF1R, IGF1 | 320 | Post radical prostatectomy associated with biochemical recurrence has a strong genetic association between IGF1R rs2016347 and IGF1 rs2946834 | Chang et al. 2013 [138] |
| rs2569733, rs9282861, rs198977, rs1800247 | KLK3, SULT1A1, KLK2, BGLAP | 670 | In post radical prostatectomy Genetic testing such as SNPs and clinicopathological data allows improvement of preoperative prediction of early biochemical recurrence | Borque et al. 2013 [139] |
| rs25489 | XRCC1 | 603 | In post radiotherapy polymorphism of XRCC1 Arg280His could be protective against the high-grade late toxicity | Langsenlehner et al. 2011 [140] |
| rs1982073, rs1800469 | TGF β1 | 322 | After radical prostatectomy followed by radiotherapy with IMRT, the genetic variants of TGF β1 in codon 10 T > C and codon -509 C > T are involved in nocturia induced by radiations | De langhe et al. 2013 [141] |
| rs1799794 | ERCC2, MLH1, ATM, XRCC3, LIG4 | 698 | Development of gastrointestinal toxicity by the mean dose and SNP in post 3D-CRT | Fachal et al. 2012 [142] |
| None | TGF β1 | 413 | No association was observed between the risk of late toxicity and haplotypes or investigated SNPs | Fachal et al. 2012 [143] |
| None | XRCC6, ABCA1, MRE11A, ALAD, MSH2, APEX1, NEIL3, BAX, NFE2L2, ATM, NOS3, CDKN1A, PAH, DCLRE1C, PRKDC, EPDR1, PTTG1, ERCC2, RAD17, ERCC4, RAD21, GSTA1, RAD9A, LIG4, REV3L, HIF1A, SART1, LIG3, SH3GL1, MED2L2, SOD2, TGFB1, MLH1, TGFB3, MAP3K7, TP53, MAT1A, XPC, CD44, XRCC1, IL12RB2, XRCC3, GSTP1, XRCC5, MPO | 637 | No association was confirmed in the current study after evaluating previous reports. The study further evaluates the SNPs P value distribution against the toxicity score. | Barnett et al. 2012 [144] |
| rs12422149, rs1077858, rs1789693, | SLCO1B3, SLCO2B1 | 538 | Patients on ADT possess three SNPs in SLCO2B1 and have a strong associated with time to progression. However, SLCO1B3 and SLCO2B1genotype patients on ADT translocate androgens efficiently and displayed median 2-year shorter TTP | Yang et al. 2011 [99] |
| - | TGFBR2 | 1765 | The post ADT patients have more risk of early relapse when TGFBR2-875GG are in homozygous condition. Combination of genetic interpretation and clinicopathological data revealed high ability to envisage the risk of failure of ADT | Teixeira et al. 2009 [145] |
| rs6900796, rs1268121 | TRMT11, WBSCR22, PRMT2, SRD5A1, PRMT7, SRD5A2, HSD17B1, UGT2B10, PRMT6, HSD17B12, HSD11B1, PRMT3, THBS1, UGT2B7, SULT2A1, CYP3A4, UGT2B4, SULT2B1, PRMT5, CYP11B2, PRMT8, METTL6, HSD3B2, CARM1, UGT1A4, HEMK1, ARSE, METTL2B, UGT1A8, UGT2B11, UGT1A5, UGT1A10, CYP19A1, ESR2, ESR1, LCMT2, UGT2A3, UGT1A9, SERPINE1, AR, UGT1A6, UGT1A7 AKR1D1, AKR1C4, UGT2A1, STS, SULT1E, HSD17B8, UGT2B28, ARSD, HSD17B3, HSD17B2, LCMT1, HSD17B7 CYP11B1, UGT1A1, HSD3B1, UGT1A3 | 304 | The study demonstrated that a strong association was observed between TRMT11 and time to ADT failure. Further, the study revealed that two out of 4 TRMT11 tag SNPs are strongly associated with time to ADT failure. | Kohli et al. 2012 [101] |
| rs6728684, rs1071738, rs3737336, rs998754, rs1045747, rs4351800 | KIF3C, PALLD, ACSL1, CDON, GABRA1, IFI30, SYT9, ETS1, ZDHHC7, has-mir-423, MTRR | 601 | In multivariate models that includes clinicopathological predictors, the genotypes IFI30 RS1045747, CDON rs3737336 and KIF3C rs6728684 emerge significant predictors for the progression of disease. More number of unfavourable type of genotypes was found to be associated with quick disease progression and lessens the prostate cancer-specific survival time after ADT | Bao et al. 2011 [102] |
| rs2051778, rs16934641, rs3763763, rs3763763 | SKAP2, GNPDA2, TACC2, BNC2, SKAP1, ZNF507, KLHL14, ZNF521, NR4A2, SPRED2, FBXO32, ALPK1, AATF | 601 | In post ADT, the clinical outcome is associated with genetic variant in TACC2, BNC2 and ALPK1. Further, the effect is cumulative when combination of ACM and genotypes of ADT of two loci of interest were investigated | Huang et al. 2012 [103] |
| rs9508016, rs2939244, rs7830622, rs9508016, rs6504145 | FLT1, ACTN2, PSMD7, ARRDC3, SKAP1, XRCC6BP1, FBXO32, FLRT3, NR2F1 | 601 | For PCSM the genetic variants in FLT1, ARRDC3, and SKAP1 are significant predictors. However, for ACM the genetic variants that are significant predictors are in FLT1 and FBXO32. Together, there was a strong combined effect on ACM and PCSM. | Huang et al. 2012 [104] |
| rs4862396, rs7986346, rs3734444 | BMP5, RXRA, NCOR2, ERG, IRS2, BMPR1A, MAP2K6 | 601 | The study suggests a strong association of genetic variants in BMP5, CASP3 and IRS2 with ACM. However, a significant association was observed in genetic variants in IRS2 and BMP5 with PCSM. In ADT patients, the greater number of unfavourable genotypes at interested loci have less time to PCSM and ACM. | Huang et al. 2012 [146] |
| - | IGF-1 | 251 | The study suggests that considering sum of all the genetic risk factors in each LD block, there is reduction in cancer-specific survival significantly when compared to 0-2 risk factors. | Tsuchiya et al. 2013 [105] |
| rs1056836 | CYP1B1 | 60 | The clinical outcome in CPRC patients to docetaxel and predictive marker is polymorphism. | Pastina et al. 2010 [120] |